Skip to main content

ADVERTISEMENT

Gina Tomaine

News
07/23/2024
The combination of low-dose ruxolitinib and anti-interferon-gamma antibody emapalumab demonstrated efficacy and safety for treating patients with hemophagocytic lymphohistiocytosis, according to a retrospective analysis.
The combination of low-dose ruxolitinib and anti-interferon-gamma antibody emapalumab demonstrated efficacy and safety for treating patients with hemophagocytic lymphohistiocytosis, according to a retrospective analysis.
The combination of low-dose...
07/23/2024
Oncology
News
07/23/2024
According to retrospective study REAL-HLH, the real-world clinical efficacy, patterns, and survival outcomes of emapalumab treatment among patients with primary hemophagocytic lymphohistiocytosis were consistent with the results a pivotal...
According to retrospective study REAL-HLH, the real-world clinical efficacy, patterns, and survival outcomes of emapalumab treatment among patients with primary hemophagocytic lymphohistiocytosis were consistent with the results a pivotal...
According to retrospective study...
07/23/2024
Oncology